Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Zilehuma Khan
Institution:
Alexion Pharmaceuticals (United States)
Observed institution:
Alexion Pharmaceuticals (United States)
OpenAlex ID:
A5148733979
Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
2026
·
Ashutosh D. Wechalekar
, Angela Dispenzieri
, et al.
·
Journal of Clinical Oncology
·
2
Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
2026
·
Ashutosh D. Wechalekar
, Angela Dispenzieri
, et al.
·
Journal of Clinical Oncology
·
1
Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study
2026
·
Jason Valent
, Jeffrey Zonder
, et al.
·
European Journal of Cancer
Clinical immunogenicity in rAAV gene therapy: Insights and implications
2026
·
Nitish Gulve
, Mariana Bego
, et al.
·
Molecular Therapy Advances
POSTER: MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
2026
·
Ashutosh Wechalekar
, Angela Dispenzieri
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
ORAL ABSTRACT: MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
2026
·
Ashutosh Wechalekar
, Angela Dispenzieri
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
2026
·
Ashutosh Wechalekar
, Angela Dispenzieri
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in κ light-chain amyloidosis.
2026
·
Ashutosh D. Wechalekar
, Angela Dispenzieri
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
8
Citation count:
3
H-index:
1
I10-index:
Year
Topic
Type
